

PHARMACEUTICAL 2023











RealRate

PHARMACEUTICAL 2023



Ventyx Biosciences Inc. Rank 36 of 446

The relative strengths and weaknesses of Ventyx Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ventyx Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Ventyx Biosciences Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 257%, being 214% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	330,688
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,359
Liabilities, Non-Current	1,146
Other Assets	40,305
Other Compr. Net Income	-1,065
Other Expenses	0
Other Liabilities	0
Other Net Income	4,710
Other Revenues	0
Property and Equipment	407
Research and Development	87,738
Selling, General and Administrative Expense	25,398

Output Variable	Value in 1000 USD
Assets	371,400
Liabilities	17,505
Expenses	113,136
Revenues	0
Stockholders Equity	353,895
Net Income	-108,426
Comprehensive Net Income	-108,958
Economic Capital Ratio	257%

